Patients using TNF-alfa inhibitors
Conditions
Interventions
Immunization of live attenuated vaccines
Sponsors
Kamei Koichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Age >= 1 year. (2) Patients using TNF-alfa inhibitors (3) Negative or borderline antibody (EIA-IgG = 500/mm3 PHA stimulation index >= 101.6 Serum IgG >= 300mg/dL (5) PSL<=1mg/day or <=2mg/2days (6) Disease activity is stable for more than 6 months
Exclusion criteria
Exclusion criteria: (1) Patients using other biological agents. (2) Patients with hematological disease or after bone marrow transplantation. (3) High disease activity. (4) Patients under immunoglobulin replacement. (5) Patients who are planned to receive inactivated VZV vaccine (they cannot receive live varicella vaccine, but can receive MR and mumps vaccine).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seropositivity rate of measles, rubella, varicella and mumps after MR, varicella and mumps vaccination | — |
Secondary
| Measure | Time frame |
|---|---|
| Seropositivity rate including additional vaccination. Analysis of risk factors for vaccine failure Presence or absence and frequency of breakthrough infection Presence or absence and frequency of vaccine strain infections Analysis of characteristics of cases with vaccine strain infections Other adverse events | — |
Contacts
Public ContactKoichi Kamei
National Center for Child Health and Development
Outcome results
None listed